Pacific Edge Limited (PFGTF)
PFGTF Stock Price Chart
Explore Pacific Edge Limited interactive price chart. Choose custom timeframes to analyze PFGTF price movements and trends.
PFGTF Company Profile
Discover essential business fundamentals and corporate details for Pacific Edge Limited (PFGTF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
2 Nov 2016
Employees
114.00
Website
https://www.pacificedgedx.comCEO
Peter Meintjes
Description
Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, and Singapore. It operates in two segments, Commercial and Research. The company offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer. It is also developing Cxbladder Resolve, a product that identifies those patients who are likely to have aggressive or more advanced bladder cancer; Cxbladder Triage, a product that identifies patients with haematuria who have a low probability of bladder cancer; Cxbladder Detect that enables the non-invasive detection of bladder and other urinary tract cancers; and Cxbladder Monitor, which allows urologists to monitor bladder cancer patients for recurrence of the disease. In addition, the company is developing Cxcolorectal, a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancers; and products for bladder, gastric, colorectal, endometrial cancers, and melanoma. Pacific Edge Limited was incorporated in 2001 and is headquartered in Dunedin, New Zealand.
PFGTF Financial Timeline
Browse a chronological timeline of Pacific Edge Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 27 May 2026
Upcoming earnings on 23 Nov 2025
Earnings released on 29 May 2025
Revenue for the quarter reached $6.18M .
Earnings released on 25 Nov 2024
EPS came in at -$0.01 falling short of the estimated -$0.01 by -5.84%, while revenue for the quarter reached $6.95M , missing expectations by -5.53%.
Earnings released on 20 May 2024
EPS came in at -$0.02 , while revenue for the quarter reached $10.81M , beating expectations by +20.60%.
Earnings released on 30 Sept 2023
EPS came in at -$0.02 falling short of the estimated -$0.01 by -96.14%, while revenue for the quarter reached $13.10M , beating expectations by +64.23%.
Earnings released on 31 Mar 2023
EPS came in at -$0.02 , while revenue for the quarter reached $10.91M , beating expectations by +61.43%.
Earnings released on 30 Sept 2022
EPS came in at -$0.01 surpassing the estimated -$0.07 by +82.05%, while revenue for the quarter reached $8.71M , beating expectations by +106.16%.
Earnings released on 31 Mar 2022
EPS came in at -$0.01 , while revenue for the quarter reached $6.07M , beating expectations by +13.66%.
Earnings released on 30 Sept 2021
EPS came in at -$0.01 falling short of the estimated -$0.01 by -33.78%, while revenue for the quarter reached $5.38M , beating expectations by +11.36%.
Earnings released on 31 Mar 2021
EPS came in at -$0.01 , while revenue for the quarter reached $4.38M .
Earnings released on 30 Sept 2020
EPS came in at -$0.01 , while revenue for the quarter reached $3.33M .
PFGTF Stock Performance
Access detailed PFGTF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.